Trial Profile
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-Media Thickness (CIMT), in Overweight Patients With Additional Risk Factors.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms AUDITOR
- 24 May 2011 Primary endpoint 'carotid intima-media thickness' has not been met, according to results published in Heart.
- 24 May 2011 Results published in Heart.
- 21 Jul 2009 Actual patient number (661) added as reported by ClinicalTrials.gov.